MX2021005685A - Metodos de inactivacion virica para la fabricacion continua de anticuerpos. - Google Patents
Metodos de inactivacion virica para la fabricacion continua de anticuerpos.Info
- Publication number
- MX2021005685A MX2021005685A MX2021005685A MX2021005685A MX2021005685A MX 2021005685 A MX2021005685 A MX 2021005685A MX 2021005685 A MX2021005685 A MX 2021005685A MX 2021005685 A MX2021005685 A MX 2021005685A MX 2021005685 A MX2021005685 A MX 2021005685A
- Authority
- MX
- Mexico
- Prior art keywords
- viral inactivation
- antibodies
- continuous manufacturing
- methods
- inactivation methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/06—Inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16761—Methods of inactivation or attenuation
- C12N2710/16763—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13061—Methods of inactivation or attenuation
- C12N2740/13063—Methods of inactivation or attenuation by chemical treatment
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Detergent Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta divulgación se relaciona con los métodos a usar en los virus de inactivación. Los métodos de inactivación del virus son para uso en la fabricación del proceso continuo de un agente biológico, tal como un anticuerpo e incluyen la separación de un eluato a un tratamiento ortogonal de pH bajo y detergente de manera simultánea en donde el tiempo para la inactivación vírica se reduce. Además, el detergente se puede agregar al sistema de amortiguación en el proceso de purificación para lograr el mismo efecto. Se conserva el agente biológico en cada caso de tratamiento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862767652P | 2018-11-15 | 2018-11-15 | |
PCT/US2019/061436 WO2020102505A1 (en) | 2018-11-15 | 2019-11-14 | Viral inactivation methods for continuous manufacturing of antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021005685A true MX2021005685A (es) | 2021-07-07 |
Family
ID=69024584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021005685A MX2021005685A (es) | 2018-11-15 | 2019-11-14 | Metodos de inactivacion virica para la fabricacion continua de anticuerpos. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20220002679A1 (es) |
EP (1) | EP3880806A1 (es) |
KR (1) | KR20210091709A (es) |
CN (1) | CN113015795A (es) |
AR (1) | AR117081A1 (es) |
AU (1) | AU2019380308A1 (es) |
BR (1) | BR112021006498A2 (es) |
CA (1) | CA3119629A1 (es) |
IL (1) | IL282944A (es) |
MX (1) | MX2021005685A (es) |
PE (1) | PE20211140A1 (es) |
SG (1) | SG11202103790WA (es) |
TW (1) | TW202039836A (es) |
WO (1) | WO2020102505A1 (es) |
ZA (1) | ZA202104083B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115873810B (zh) * | 2022-12-26 | 2024-02-09 | 苏州良辰生物医药科技有限公司 | 一种鼠白血病病毒的纯化方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0674531A1 (de) * | 1992-12-16 | 1995-10-04 | IMMUNO Aktiengesellschaft | Verfahren zur herstellung eines virussicheren biologischen präparates |
IL136552A (en) * | 2000-06-05 | 2005-05-17 | Omrix Biopharmaceuticals Ltd | Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration |
US9428546B2 (en) * | 2010-07-30 | 2016-08-30 | Pfizer Inc. | Tandem purification of proteins |
WO2014004103A1 (en) * | 2012-06-29 | 2014-01-03 | Emd Millipore Corporation | Methods for inactivating viruses during a protein purification process |
JP6465800B2 (ja) | 2012-08-06 | 2019-02-06 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | エンベロープウイルスを不活化するための方法および組成物 |
CN105722523B (zh) * | 2013-11-15 | 2022-06-14 | 豪夫迈·罗氏有限公司 | 使用环保洗涤剂的病毒灭活方法 |
WO2015158776A1 (en) * | 2014-04-15 | 2015-10-22 | Boehringer Ingelheim International Gmbh | Methods, apparatuses, and systems for continuously inactivating a virus during manufacture of a biological product |
WO2016207328A1 (en) * | 2015-06-24 | 2016-12-29 | Glycotope Gmbh | PROCESS FOR THE PURIFICATION OF γ-CARBOXYLATED POLYPEPTIDES |
-
2019
- 2019-11-14 WO PCT/US2019/061436 patent/WO2020102505A1/en unknown
- 2019-11-14 EP EP19828357.4A patent/EP3880806A1/en active Pending
- 2019-11-14 AR ARP190103352A patent/AR117081A1/es unknown
- 2019-11-14 US US17/292,652 patent/US20220002679A1/en active Pending
- 2019-11-14 CA CA3119629A patent/CA3119629A1/en active Pending
- 2019-11-14 SG SG11202103790WA patent/SG11202103790WA/en unknown
- 2019-11-14 PE PE2021000699A patent/PE20211140A1/es unknown
- 2019-11-14 BR BR112021006498A patent/BR112021006498A2/pt not_active IP Right Cessation
- 2019-11-14 KR KR1020217014291A patent/KR20210091709A/ko unknown
- 2019-11-14 MX MX2021005685A patent/MX2021005685A/es unknown
- 2019-11-14 CN CN201980074580.XA patent/CN113015795A/zh active Pending
- 2019-11-14 AU AU2019380308A patent/AU2019380308A1/en active Pending
- 2019-11-14 TW TW108141336A patent/TW202039836A/zh unknown
-
2021
- 2021-05-05 IL IL282944A patent/IL282944A/en unknown
- 2021-06-14 ZA ZA2021/04083A patent/ZA202104083B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA202104083B (en) | 2023-01-25 |
EP3880806A1 (en) | 2021-09-22 |
SG11202103790WA (en) | 2021-05-28 |
PE20211140A1 (es) | 2021-06-25 |
BR112021006498A2 (pt) | 2021-07-06 |
CN113015795A (zh) | 2021-06-22 |
KR20210091709A (ko) | 2021-07-22 |
CA3119629A1 (en) | 2020-05-22 |
JP2022507369A (ja) | 2022-01-18 |
TW202039836A (zh) | 2020-11-01 |
AR117081A1 (es) | 2021-07-07 |
WO2020102505A1 (en) | 2020-05-22 |
IL282944A (en) | 2021-06-30 |
AU2019380308A1 (en) | 2021-05-13 |
US20220002679A1 (en) | 2022-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502003A1 (en) | Cyclic sulfamide compounds and methods of using same | |
WO2016100261A3 (en) | Method of treating cancer with cgamp or cgasmp | |
PH12018500664A1 (en) | Anti-lag3 antibodies and uses thereof | |
MX2020003798A (es) | Metodos para la purificacion de arilsulfatasa a. | |
MX2017015666A (es) | Agentes de anticuerpos similares al receptor de celulas t, especificos para peptidos de proteina latente de membrana 2a del virus de epstein-barr (ebv) presentado por antigeno leucocitario humano (hla). | |
EA201791443A1 (ru) | Естественные киллерные клетки и их применения | |
BR112015022790A8 (pt) | molécula biespecífica, composição farmacêutica, método de tratamento de uma infecção por vírus latente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus persistente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus inativo em um indivíduo em necessidade de tal tratamento, método para exterminar uma célula que contém um genoma viral, e, método para exterminar uma célula que expressa uma proteína viral | |
WO2015048330A3 (en) | On-column viral inactivation methods | |
MY194289A (en) | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, and Methods of use | |
DE602005009634D1 (de) | Niedrigkonzentrations-Lösungsmittel/Detergensprozess von Immunglobulin mit Vorbehandlungsschritt | |
SG10201908027QA (en) | Use of alkaline washes during chromatography to remove impurities | |
EA201790160A1 (ru) | Способы лечения инфекций, вызываемых вирусами гепатита b и гепатита d | |
PH12016502554B1 (en) | A dengue virus chimeric polyepitope composed of fragments of non structural proteins and its use in an immunogenic composition against dengue virus infection | |
EA201990593A1 (ru) | Непрерывный способ для снижения гетерогенности терапевтического белка | |
MX2016017115A (es) | Metodos y reactivos para la purificacion de proteinas. | |
EA202192923A1 (ru) | Антитела и способы лечения инфекции, вызываемой вирусом гриппа а | |
MX2021005685A (es) | Metodos de inactivacion virica para la fabricacion continua de anticuerpos. | |
PH12020500176A1 (en) | A composition for treating and/or preventing hepatitis b virus infection and the use thereof | |
MX2022002231A (es) | Composiciones de anticuerpos y metodos para tratar la infeccion por el virus de la hepatitis b. | |
BR112016027818A2 (pt) | composições purificadas de proteínas ivig e kh para modular linfócitos e tratar virus da hepatite b. | |
MX2019013160A (es) | Metodos de tratamiento selectivo del asma usando antagonistas de il-17. | |
AU2017260580A1 (en) | Reagents for treatment of hepatitis B virus (HBV) infection and use thereof | |
TR201910305T4 (tr) | Viral enfeksiyonları tedavi etmek için bileşikler. | |
GB202006786D0 (en) | Means and methods to treat viral infections | |
UA85733C2 (ru) | Способ инактивации вирусов при получении церулоплазмина |